Ginkgo Bioworks
VC Fund
Boston, United States
Ginkgo Bioworks is a biotechnology firm. It is a developer of biological engineering products and custom microbes across multiple markets. It designs, engineer, develops, tests, and licenses organisms. It discovers molecules in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. It also provides probiotic bacteria toprotect the body from dangerous infections, and it generates libraries of molecules. It serves cultured ingredients, carbon mitigation, probiotics, and natural product discovery markets.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Ginkgo Bioworks invests in
Stages Ginkgo Bioworks invests in
Countries Ginkgo Bioworks invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 4 (50%)
- Health Care 2 (25%)
- Renewable Energy 2 (25%)
- Organic 1 (13%)
- Military 1 (13%)
Stage
- Series A 3 (38%)
- Funding Round 2 (25%)
- Seed 1 (13%)
- Post-IPO Equity 1 (13%)
Country
- United States 5 (63%)
- Israel 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anna Marie Wagner
SVP, Corporate Development
|
SVP, Corporate Development | Total investments: 2 | Find email | |
Barry Canton
Founder
|
Founder | Total investments: 0 | Find email | |
Behzad Mahdavi
Senior Vice President Biopharma Manufacturing & Life Sciences Tools
|
Senior Vice President Biopharma Manufacturing & Life Sciences Tools | Total investments: 0 | Find email | |
Daniel Robinson
Platform Strategy & Development
|
Platform Strategy & Development | Total investments: 0 | Find email | |
Han Xu
Senior Product Designer
|
Senior Product Designer | Total investments: 0 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Phytolon
|
Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability | Aug 13, 2025 | |
|
Phytolon
|
Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability | $14.5M / Series A / Jul 05, 2022 | |
Cambium
|
Cambium develops biomaterials for fields such as defense, space transport, aerospace, and renewable energy. Leveraging the Deep Tech convergence between synthetic biology, materials science, computation & automation, it delivers radical step changes in advanced material performance and sustainability to improve today’s products and enabletomorrow’s. | $8M / Seed / Sep 14, 2021 | |
Allonnia
|
Allonnia is a bioremediation company focused on waste management. | Series A / Oct 22, 2020 | |
Synlogic
|
Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. The company's lead programs target patients with rare genetic metabolic diseases, including phenylketonuria and secondary hyperoxaluria. Synlogic is also hard at work on synthetic biotics to address more prevalentconditions, including inflammatory bowel disease, cancer, and other metabolic conditions. | Post-IPO Equity / Jun 12, 2019 | |
Genomatica
|
Genomatica develops biobased process technologies that enable a better way to produce widely-used chemicals, from alternative feedstocks, with better economics, sustainability, and performance. Genomatica has earned widespread acclaim for its technology; has commercialized processes for the chemical butanediol (for biodegradable plastics andapparel) and for butylene glycol (cosmetics and personal care), and is working on bio-nylon. Awards include the Kirkpatrick Award, for “the most noteworthy chemical engineering technology commercialized in the world” and the ICIS Innovation Award for its Brontide(TM) butylene glycol. | Oct 03, 2018 | |
Joyn Bio
|
Joyn Bio is a joint venture founded by Bayer and Ginkgo Bioworks developing probiotics for plants to provide growers with next generation solutions to their biggest challenges. Joyn Bio’s first area of focus will be on engineering microbes that provide cereal crops with their nitrogen needs to reduce agriculture’s reliance on nitrogen fertilizerand its environmental impact. Joyn Bio brings together microbiologists, synthetic biologists, plant scientists, and ecologists at its headquarters in Boston, Massachusetts and its plant research facility in West Sacramento, California. | $100M / Series A / Mar 20, 2018 | |
|
Joyn Bio
|
Joyn Bio is a joint venture founded by Bayer and Ginkgo Bioworks developing probiotics for plants to provide growers with next generation solutions to their biggest challenges. Joyn Bio’s first area of focus will be on engineering microbes that provide cereal crops with their nitrogen needs to reduce agriculture’s reliance on nitrogen fertilizerand its environmental impact. Joyn Bio brings together microbiologists, synthetic biologists, plant scientists, and ecologists at its headquarters in Boston, Massachusetts and its plant research facility in West Sacramento, California. | $100M / Series A / Sep 14, 2017 |
Co-Investors
Viking Global Investors
3 deals together
Arkin Holdings
2 deals together
Bayer
2 deals together
Leaps by Bayer
2 deals together
Nextgen Nutrition
2 deals together
Trendlines Group
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Ginkgo Bioworks invest in?
Ginkgo Bioworks invests primarily in Biotechnology, Health Care and Renewable Energy startups, most often at Series A and Funding Round stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ginkgo Bioworks?
Public channels for Ginkgo Bioworks include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Ginkgo Bioworks?
The team at Ginkgo Bioworks includes Anna Marie Wagner (SVP, Corporate Development), Barry Canton (Founder) and Behzad Mahdavi (Senior Vice President Biopharma Manufacturing & Life Sciences Tools), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
